ArticleClinical epidemiology2025
Esophageal and Gastric Cancer Incidence and Mortality Trends in Norway, 1993-2022: A Registry-Based Study.
Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esophageal and gastric cancers account for nearly 1.5 million new cases and 1.1 million deaths annually worldwide. In western countries, the incidence of esophageal cancer is rising while that of gastric cancer has decreased, although the pattern varies between the morphological types and subsites. We aim to describe the burden of esophageal and gastric cancers in Norway by providing national trends in incidence and mortality, separately for esophageal squamous cell carcinoma (SCC) and adenocarcinoma (AC), and for gastric ACs by gastric subsites. Methods: We extracted information about all esophageal (ICD10 C15) and gastric cancer (ICD10 C16) patients diagnosed 1993‒2022 from the Cancer Registry of Norway. Age-standardized (European standard population) rates and performed joinpoint regression analyses were calculated to examine trends in incidence and mortality over time, for esophageal cancer SCC and AC and by subsite for gastric AC (cardia: ICD10 C16.0 and non-cardia: ICD10 C16.1-9). We used annual percent change (APC) and weighted average APC (AAPC), stratified by sex, age group, and stage at diagnosis. Results: During 1993-2022, 6,433 esophageal cancers (2,616 SCC, 3,817 AC) and 14,453 gastric AC were diagnosed, and 4,683 esophageal and 10,421 gastric AC deaths occurred. The incidence and mortality of esophageal ACs increased whereas the rates for esophageal SCC declined in men and were stable in women. The highest AC incidence and mortality increases were seen in men (incidence AAPC = 2.8) and ages ≥70 years (incidence AAPC = 5.9). In contrast, the incidence and mortality of gastric cancer decreased over time, most pronounced for non-cardia gastric AC (incidence AAPC men =-5.3, women =-3.9). Conclusion: The incidence and mortality of esophageal AC has increased in Norway during the last decades, most pronounced in men, ages ≥70 years. The rates of SCCs decreased, although trends differed between sex and age groups. The incidence and mortality of gastric AC decreased in all age-groups for both sexes, especially for non-cardia gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.